A Multi-center Prospective Study of Branch Atheromatous Disease in China

Magnetic Resonance Imaging Clinical Trial

Official title:

A Multi-center Prospective Study of Branch Atheromatous Disease in China

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04973774
• Other study ID #: BADstudy
• Status: Recruiting
• Start date: June 1, 2021
• Est. completion date: June 1, 2025

Study information

• Verified date: July 2021
• Source: Peking Union Medical College Hospital
• Contact: Shengde Li, PhD,MD
• Phone: 17896002828
• Email: lishengde.medicine[@]qq.com
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Branch atheromatous disease (BAD), is regarded as one of the important etiologies for acute isolated subcortical infarction, especially in Asian population. However, due to the fact that the existing imaging techniques cannot depict small vessel changes, the clinical diagnosis, therapy and research of BAD are facing challenges. We have started a multi-center prospective observational study of BAD in China, aiming at establishing a large-sample clinical-radiological cohort of BAD, analyzing predictors for functional outcome, and exploring the efficacy of tirofiban on BAD. A standardized Case Report Form (and eCRF on website) is used to collect baseline and follow-up information on epidemiological, clinical, radiological（MRI, SWI, MRA, HRMRI,3TVWI）and blood test. The primary outcome was mRS on 90 days with blind evaluation.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 600
• Est. completion date: June 1, 2025
• Est. primary completion date: May 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Age:18-80years

2. Acute cerebral infarction:if the clinical manifestations are TIA, new infarct lesions should be found on DWI at the same time.

3. The time from onset to enrollment is less than 72 hours. If the onset time was unknown, the time of last known free of new ischemic symptoms to enrollment is less than 72h.

4. Meet the following radiological criterial: 1) DWI infarct: single (isolated) deep (subcortical) infarct. 2) The culprit vessels are the lenticulostriate artery or the para-pontine median artery, and the infarct lesion on DWI conforms to one of the following characteri stics(A/B): A. Lenticulostriate artery: ? "comma-like" infarct lesions with "fan-shaped" extension from bottom to top in the coronary position; OR ? =3 layers (layer thickness 5-7 mm) on axial DWI images of the head; B. Para-pontine median artery: the infarct lesion extends from the deep pons to the ventral pons on the axial DWI of the head. 3) No =50% stenosis on the parent artery of the criminal vessel (i.e. corresponding basilar or middle cerebral artery) (confirmed by MRA or CTA or DSA). 5.Signed informed consent by the patient or legally authorised representatives

Exclusion Criteria:

1. Intracranial hemorrhagic diseases, vascular malformations, aneurysms, brain abscesses, malignant space occupying lesions or other non-ischemic intracranial lesions observed by baseline head CT and MRI, MRA/CTA/DSA;

2. There was =50% stenosis of extracranial vessels with ipsally serial relationship

3. Cardiogenic embolism: atrial fibrillation, myocardial infarction, valvular heart disease, dilated cardiomyopathy, infective endocarditis, atrioventricular block disease, heart rate less than 50 beats /min

4. Have received or plan to receive acute endovascular treatment after onset of the disease

5. stroke caused by other clear causes, such as moyamoya disease, arterial dissection, vasculitis, etc

6. mRS score prior to the onset of the disease was =2 points

7. Known malignant tumor

8. Life expectancy =6 months

9. Can not tolerate 3T MRI examination

10. Pregnant or lactating women

11. Participation in another clinical within 3 months before enrollment, or taking part in another ongoing study.

Related Conditions & MeSH terms

• Cerebral Infarction
• Disease
• Infarction
• Magnetic Resonance Imaging

Locations

Country	Name	City	State
China	Shengde li	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Peking Union Medical College Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	modified ranking score	modified ranking score on 90 days, range:0-6scores; higher score means worse outcome	90 days